• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

Olmutinib

Product ID O456505
Cas No. 1353550-13-6
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $55.70 In stock
25 mg $121.10 In stock
100 mg $352.30 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Olmutinib is an inhibitor of EGFR. It is selective for mutant forms of EGFR, leading to cell death of EGFR-expressing tumor cells. Olmutinib reverses ABCG2-mediated multidrug resistance in cancer cells.

Product Info

Cas No.

1353550-13-6

Purity

≥98%

Formula

C26H26N6O2S

Formula Wt.

486.59

Chemical Name

N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide

IUPAC Name

N-{3-[(2-{[4-(4-Methyl-1-piperazinyl)phenyl]amino}thieno[3,2-d]pyrimidin-4-yl)oxy]phenyl}acrylamide

Synonym

HM61713, BI-1482694

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

O456505 MSDS PDF

Info Sheet

O456505 Info Sheet PDF

References

Zhang W., Fan Y., et al. Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells. Front Pharmacol. 9:1097 (2018). PMID: 30356705.

Noh Y., Yoon S., et al. A Safety, Pharmacokinetic, Pharmacogenomic and Population Pharmacokinetic Analysis of the Third-Generation EGFR TKI, Olmutinib (HM61713), After Single Oral Administration in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2019. PMID: 31125491.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only